financetom
Business
financetom
/
Business
/
Tapestry forecasts annual profit below estimates on tariff pain, shares plunge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tapestry forecasts annual profit below estimates on tariff pain, shares plunge
Aug 14, 2025 4:36 AM

(Reuters) -Tapestry forecast annual profit below estimates on Thursday, as the Coach handbag maker grapples with higher tariff costs, sending the company's shares down 8% in premarket trading.

The company estimates a $160-million hit from the U.S. import duties, which could result in an about 230-basis-point impact on its fiscal 2026 operating margin.

Tapestry primarily makes its Coach and Kate Spade handbags in countries such as Vietnam, Cambodia, the Philippines and India.

The Trump administration's unpredictable trade policies have shaken consumer sentiment and disrupted businesses and supply chain worldwide.

Tapestry's warning on Thursday is in line with the broader luxury sector slowdown that has hurt bellwethers such as Gucci-owner Kering and French luxury group LVMH .

U.S. consumer spending falling unexpectedly in May has also compounded concerns for companies such as Tapestry that have been ramping up efforts to attract younger customers by introducing new accessories and collections.

The company expects fiscal 2026 earnings per share to be in the range of $5.30 to $5.45, compared with analysts estimates of $5.49 per share, as per data compiled by LSEG. The forecast accounts for about 60 cents of incremental tariffs.

However, it expects fiscal 2026 revenue to be about $7.2 billion, compared with analysts' estimates of $7.11 billion, owing to steady demand for its Coach Tabby and Empire bags.

Shares of the company have risen about 74% this year on the back of the popularity of its Coach brand.

The push to add bag charms are also attracting millennial and Gen Z customers in regions such as North America, China and Europe.

This helped the company post quarterly sales of $1.72 billion that beat analysts' estimates of $1.68 billion.

Adjusted profit for the fourth quarter ended June 28 was $1.04 per share, topping estimates by 2 cents.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Coterra Energy to Acquire Certain Assets of Franklin Mountain Energy, Avant Natural Resources for $3.95 Billion
--Coterra Energy to Acquire Certain Assets of Franklin Mountain Energy, Avant Natural Resources for $3.95 Billion
Nov 13, 2024
07:15 AM EST, 11/13/2024 (MT Newswires) -- Price: 25.47, Change: +0.26, Percent Change: +1.03 ...
This Stock Surges Over 20% In Pre-Market Following 66% Gains In Previous Session After Embracing Bitcoin As Treasury Asset
This Stock Surges Over 20% In Pre-Market Following 66% Gains In Previous Session After Embracing Bitcoin As Treasury Asset
Nov 13, 2024
Genius Group Limited ( GNS ) experienced a significant boost in its stock value, climbing 20% in pre-market trading on Wednesday, as per Benzinga Pro. This surge followed the company’s announcement to adopt Bitcoin (CRYPTO: BTC) as its main treasury asset. As per a press release, Genius Group ( GNS ) plans to allocate 90% of its current and future...
Coterra Energy to buy oil and gas assets for $3.95 billion
Coterra Energy to buy oil and gas assets for $3.95 billion
Nov 13, 2024
Nov 13 (Reuters) - U.S. oil and gas producer Coterra Energy ( CTRA ) said on Wednesday it would acquire certain assets of Avant Natural Resources and its affiliates and Franklin Mountain Energy for an aggregate consideration of $3.95 billion in cash and stock deals. ...
BioNTech to Acquire Biotheus; Shares Rise Pre-Bell
BioNTech to Acquire Biotheus; Shares Rise Pre-Bell
Nov 13, 2024
07:05 AM EST, 11/13/2024 (MT Newswires) -- BioNTech (BNTX) said Wednesday it has agreed to acquire biotechnology company Biotheus. Under the terms of the deal, BioNTech will acquire 100% of Biotheus for $800 million, mainly in cash with a small portion of American depositary shares, plus additional performance-based contingent payments of up to $150 million if the milestones are met....
Copyright 2023-2026 - www.financetom.com All Rights Reserved